 |
BioWorld-International-2002-04-17
Medivir, Roche In $42M Pact For Preclinical HIV Compound
Medivir, Roche In $42M Pact For Preclinical HIV Compound
Swedish biotechnology firm Medivir AB unveiled Monday its biggest drug development deal to date a licensing agreement worth up to US$42 million with F. Hoffmann-La Roche Ltd. for Medivir’s candidate HIV treatment, MV026048. (BioWorld International)